FastkD3: A Protein Regulator and Potential Drug Target (G79072)

Target Name: FASTKD3

NCBI ID: G79072

FASTKD3

FastkD3: A Protein Regulator and Potential Drug Target

FastkD3 (FAKD3_HUMAN) is a protein that is expressed in various tissues of the human body. It is a key regulator of cell signaling, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article , we will discuss the research on FastkD3 and its potential as a drug target or biomarker.

Structure and Function

FastkD3 is a 21-kDa protein that is expressed in various tissues of the human body, including muscle, liver, and brain. It is composed of a N-terminal alpha-helix, a middle alpha-helix, and a C-terminal T -loop. The protein has a pI of 9.0, and its cytoplasmic localization suggests that it is primarily expressed in the cytoplasm.

FastkD3 is involved in the regulation of several cellular processes, including cell signaling, DNA replication, and apoptosis. Its functions are primarily attributed to its role in the F-actin signaling pathway, which is a critical pathway involved in many cellular processes, including cell adhesion, migration, and invasion.

Mutations in the FastkD3 gene have been observed to cause various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that FastkD3 mutations are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally , FastkD3 mutations have also been observed to increase the risk of cancer, particularly in breast and ovarian cancers.

Drug Target Potential

FastkD3 has been identified as a potential drug target due to its involvement in the F-actin signaling pathway and its association with various diseases. Several studies have shown that inhibiting FastkD3 activity can lead to therapeutic effects in these diseases. For example, studies have shown that inhibiting FastkD3 activity can lead to a reduction in the size of cancer tumors and improve the survival rate in neurodegenerative diseases.

FastkD3 has also been shown to be a potential biomarker for several diseases, including cancer and neurodegenerative diseases. Its expression has been observed in various tissues of the human body, including cancer, and its levels have been shown to be elevated in individuals with certain diseases . For example, studies have shown that FastkD3 levels are elevated in individuals with breast cancer and that inhibiting FastkD3 activity can lead to a reduction in cancer cell proliferation.

Conclusion

In conclusion, FastkD3 is a protein that is involved in the regulation of cell signaling and has been implicated in a variety of diseases, including cancer and neurodegenerative diseases. Its dysfunction has been associated with numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. . As a result, FastkD3 has emerged as a promising drug target and a potential biomarker for the treatment of these diseases. Further research is needed to fully understand the functions of FastkD3 and its potential as a drug.

Protein Name: FAST Kinase Domains 3

Functions: Required for normal mitochondrial respiration (PubMed:20869947). Increases steady-state levels and half-lives of a subset of mature mitochondrial mRNAs MT-ND2, MT-ND3, MT-CYTB, MT-CO2, and MT-ATP8/6. Promotes MT-CO1 mRNA translation and increases mitochondrial complex IV assembly and activity (PubMed:27789713)

The "FASTKD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FASTKD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets